AstraZeneca Pharma India has registered a net loss of Rs 33 crore for the quarter ended March 31, 2012, due to a voluntary recall of sterile products and temporary halt of production at its Bangalore facility. The company had posted a net profit of Rs 8.35 crore for the quarter ended March 31, 2011.
Total income of the company stood at Rs 91.78 crore for the quarter ended March 31, 2012. It was Rs 126.73 crore for the corresponding period previous fiscal, up by 27.58%.
The company said its board of directors has recommended a dividend of Rs 3.50 per equity share of face value of Rs 2 each for the financial year ended March 31, 2012.
AstraZeneca operates through two entities, AstraZeneca Pharma India and AstraZeneca India in the country.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: